Interpace Biosciences (OTCID: IDXG) expects preliminary unaudited revenue for the third quarter of fiscal year 2026 to range from $10.1 million to $10.4 million. This projection indicates year-over-year growth of approximately 15% to 18% compared to the same period in 2025.

The anticipated performance also represents a sequential increase of roughly 11% to 14% against the second quarter of 2026, where revenue stood at $9.1 million. The company announced these figures on October 14, 2026, highlighting continued top-line momentum.

Preliminary Financial Outlook

The estimated revenue is preliminary and unaudited, based on information currently available to management. Interpace notes that actual results may differ materially from this range due to ongoing quarter-end closing procedures and subsequent review by its independent registered public accounting firm. Complete financial results for Q3FY26 are expected to be reported at a later date.

What the Numbers Show

The data reveals a consistent acceleration in revenue conversion. While the quarter-over-quarter growth band of 11% to 14% suggests steady operational scaling, the wider year-over-year range of 15% to 18% indicates that the company is gaining market share or volume faster than the previous year's baseline. The midpoint of the projected revenue ($10.25 million) exceeds the prior quarter's actuals by $1.15 million, signaling a robust sequential trajectory without reliance on non-recurring items mentioned in the preliminary release.

Company Profile

Interpace Biosciences operates as an emerging leader in personalized medicine, specializing in molecular diagnostic tests. Its commercialized thyroid tests, ThyGeNEXT and ThyraMIR v2, are used together to support the evaluation of indeterminate thyroid nodules.

Interpace Biosciences, Inc. (OTCID: IDXG) will implement a 1-for-5 reverse stock split effective August 27, 2026, in a strategic move to pursue a Nasdaq Capital Market listing.

The corporate action reduces the company’s outstanding share count from approximately 27.7 million to 5.5 million. The split is designed to help the firm meet the minimum bid price requirement for Nasdaq, though management noted there is no guarantee of compliance or subsequent listing approval.

Mechanics of the Split

The reverse split becomes effective at 12:01 am Eastern Time on August 27, 2026. Trading on the OTCID quotation system will resume on a split-adjusted basis at the market open that same day.

Key structural changes include:

• Temporary ticker symbol change to IDXGD for 20 trading days.
• New CUSIP number: 46062X402.
• No fractional shares issued; fractional entitlements are rounded up to the nearest whole share.
• Par value remains unchanged at $0.01 per share.

Proportional adjustments will apply to outstanding stock options, restricted stock units, and equity incentive plans. Shareholders holding book-entry shares through brokers or banks require no action, as accounts will be adjusted automatically by transfer agent Equiniti Trust Company.

Listing Requirements and Outlook

Stockholders approved the authority for the Board of Directors to effect a reverse split between a one-for-two and one-for-ten ratio at the annual meeting held on August 20, 2026. The Board subsequently selected the 1-for-5 ratio.

Beyond the bid price requirement, Interpace must satisfy additional Nasdaq criteria, including maintaining a market value of unrestricted publicly held shares of at least $15 million. CEO Tom Burnell stated that uplisting is intended to support planned growth and attract a broader investor base.

Interpace Biosciences operates in personalized medicine, offering molecular diagnostic tests such as ThyGeNEXT and ThyraMIRv2 for thyroid cancer diagnosis.